China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene
Inspections Report 20% GMP Non-Compliance
Executive Summary
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
You may also be interested in...
China Suspends GSK Tender Qualification Under Dutasteride Ban
GSK becomes the second foreign pharma firm in recent months to be hit with a ban on the import, sale and use of a product by increasingly assertive Chinese regulatory authorities.
China Suspends GSK Tender Qualification Under Dutasteride Ban
GSK becomes the second foreign pharma firm in recent months to be hit with a ban on the import, sale and use of a product by increasingly assertive Chinese regulatory authorities.
BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.